PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.44%
Positive EBIT growth while AVXL is negative. John Neff might see a substantial edge in operational management.
10.44%
Positive operating income growth while AVXL is negative. John Neff might view this as a competitive edge in operations.
10.28%
Positive net income growth while AVXL is negative. John Neff might see a big relative performance advantage.
12.12%
Positive EPS growth while AVXL is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
10.49%
Positive diluted EPS growth while AVXL is negative. John Neff might view this as a strong relative advantage in controlling dilution.
2.21%
Share count expansion well above AVXL's 1.76%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.06%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-28.93%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4997.65%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
52.56%
Positive OCF/share growth while AVXL is negative. John Neff might see a comparative advantage in operational cash viability.
56.42%
3Y OCF/share CAGR above 1.5x AVXL's 6.05%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
-10058.37%
Negative 10Y net income/share CAGR while AVXL is at 14.86%. Joel Greenblatt sees a major red flag in long-term profit erosion.
92.69%
Positive 5Y CAGR while AVXL is negative. John Neff might view this as a strong mid-term relative advantage.
51.37%
Positive short-term CAGR while AVXL is negative. John Neff would see a clear advantage in near-term profit trajectory.
741.48%
10Y equity/share CAGR above 1.5x AVXL's 167.29%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
108.54%
Below 50% of AVXL's 308.55%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-89.94%
Negative 3Y equity/share growth while AVXL is at 9.89%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-17.83%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-40.69%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
499.58%
Debt growth of 499.58% while AVXL is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
-14.73%
Our R&D shrinks while AVXL invests at 29.60%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
3.54%
SG&A declining or stable vs. AVXL's 18.88%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.